par Rozencweig, Marcel ;Kenis, Yvon ;Atassi, Ghanem
Référence CANCER CHEMOTHER.REP., 6, 2, page (131-136)
Publication Publié, 1975
Article révisé par les pairs
Résumé : The previously assessed superiority of the DNA adriamycin complex over adriamycin alone in L1210 murine leukemia depends on the strain of mice, the line of L1210, and the route of tumor cell inoculation. In a phase I trial, 6 to 12 hr infusions of the DNA adriamycin complex were given at a dosage schedule of 75 mg/m2 every 3 wk. The subacute drug induced toxic effects are similar to those encountered after direct injection of the free adriamycin. Cardiac toxic effects could not be evaluated accurately in this trial. A preliminary pharmacokinetic study demonstrates, in mice as well as in man, striking differences between free and bound adriamycin with regard to initial plasma levels and patterns of clearance from the plasma. These findings are not yet completely understood.